Publication Date | SPC No. | SPC Category | Details Rows may repeat to show multiple inventors or applicants depending on "Sort By" |
---|
19 April 2017
(Journal 6674)
| SPC/GB12/008 | Extensions Lodged | Applicant: Laboratoire Theramex 6 Avenue Albert II, 98000 Monaco (MC)
Product: Nomegestrol acetate + free or esterified estradiol
Product Type: Medicinal Authorised: UK EU/1/11/690/001 27 July 2011 UK EU/1/11/690/002 27 July 2011
Authorised Extension: C(2012)2827 20 April 2012
Patent No: EP1334725 Title: Estroprogestative Contraceptive Composition
SPC No: SPC/GB12/008 Date Lodged: 21 March 2017 |
19 April 2017
(Journal 6674)
| SPC/GB12/051 | Rejected | Applicant: The Kennedy Institute for Rheumatology Research 16 St John's Lane, LONDON, EC1M 4BS
Product: Adalimumab
Product Type: Medicinal Authorised: CH (CH) 56221 16 April 2003 UK EU/1/03/256/001 8 September 2003 UK EU/1/03/256/002 8 September 2003 UK EU/1/03/256/003 8 September 2003 UK EU/1/03/256/004 8 September 2003 UK EU/1/03/256/005 8 September 2003 UK EU/1/03/256/006 8 September 2003
Authorised Extension:
Patent No: EP1941904 Title: TNF antagonists for use in adjunctive therapy to methotrexate in the treatment of autoimmune diseases.
SPC No: SPC/GB12/051 Date Lodged: 15 November 2012 |
19 April 2017
(Journal 6674)
| SPC/GB13/004 | Granted | Applicant: Takeda Pharmaceutical Company Limited 1-1 Doshomachi 4-chome, Chuo-ku,, Osaka 541-0045, Japan
Product: Ceftaroline fosamil or a pharmaceutically acceptable salt thereof
Product Type: Medicinal Authorised: UK EU/1/12/785/001 23 August 2012
Authorised Extension:
Patent No: EP1043327 Title: Phosphonocephem derivatives, process for the preparation of the same , and use thereof
SPC No: SPC/GB13/004 Date Granted: 27 March 2017 Maximum Period Expires On: 16 December 2023 |
19 April 2017
(Journal 6674)
| SPC/GB13/035 | Granted | Applicant: Astellas Pharma Inc. No.3-11, Nihonbashi-Honcho, 2-chome, Chuo-ku, Tokyo 103-8411, Japan
Product: Mirabegron or a salt thereof
Product Type: Medicinal Authorised: UK EU/1/12/809/001-014 7 January 2013
Authorised Extension:
Patent No: EP1559427 Title: Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient.
SPC No: SPC/GB13/035 Date Granted: 27 March 2017 Maximum Period Expires On: 6 January 2028 |
19 April 2017
(Journal 6674)
| SPC/GB13/078 | Granted | Applicant: Allergan, Inc. 2525 Dupont Drive, Irvine, California 92612, United States of America
Product: Botulinum toxin type A
Product Type: Medicinal Authorised: FI 263103-5/2012 16 January 2013 UK PL 00426/0118 - 0061 4 September 2013 UK PL 00426/0074 - 0139 4 September 2013 UK PL 00426/0119 - 0047 4 September 2013
Authorised Extension:
Patent No: EP2145629 Title: Use of neurotoxin therapy for treatment of urological and related disorders
SPC No: SPC/GB13/078 Date Granted: 27 March 2017 Maximum Period Expires On: 14 July 2023 |
19 April 2017
(Journal 6674)
| SPC/GB15/053 | Granted | Applicant: AstraZeneca UK Limited 2 Kingdom Street, London, W2 6BD
Product: Cangrelor or a pharmaceutically acceptable salt thereof
Product Type: Medicinal Authorised: UK EU/1/15/994/001 23 March 2015
Authorised Extension:
Patent No: EP1007094 Title: Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying.
SPC No: SPC/GB15/053 Date Granted: 27 March 2017 Maximum Period Expires On: 10 December 2022 |
19 April 2017
(Journal 6674)
| SPC/GB17/024 | Lodged | Applicant: ICOS CORPORATION Lilly Corporate Center, Indianapolis, IN 46285, USA
Product: Idelalisib or a pharmaceutically acceptable salt thereof
Product Type: Medicinal Authorised: UK EU/1/14/938/001-002 19 September 2014
Authorised Extension:
Patent No: EP1761540 Title: Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
SPC No: SPC/GB17/024 Date Lodged: 20 March 2017 |